NSE filing, NSE: MOL. Summary written from the filing by ALFA Finder's alert engine.
Meghmani Organics Ltd: key numbers
- Share price
- ₹54.37
- Market cap
- ₹1,383 Cr
- Revenue (annual)
- ₹2,174 Cr
- Net profit (annual)
- ₹28.74 Cr
- P/E (TTM)
- 21.5×Sector 34.1×
- Promoter holding
- 48.95%+0.00% QoQ
- FII holding
- 0.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Meghmani Organics Ltd
All →Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
Meghmani Organics Board Meeting Date
Meghmani Organics will hold a board meeting on 4 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The meeting is a future notice, so no results are yet reported.
Meghmani Organics Other Announcement
Meghmani Organics Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Meghmani Organics Acquisition
Meghmani Organics Limited received an NCLT Ahmedabad Bench order sanctioning the Scheme of Amalgamation of its wholly-owned subsidiaries, Kilburn Chemicals Limited and Meghmani Crop Nutrition Limited, with itself.
Meghmani Organics Annual General Meeting
Meghmani Organics Limited held its 7th Annual General Meeting on September 8, 2026. The meeting concluded successfully with all items of business transacted as proposed.
Meghmani Organics Other Announcement
Meghmani Organics Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details environmental, social, and governance initiatives.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.